RETURN
PLEASE NOTE - you must be logged into Confluence to add a discussion item
If you do not have a Confluence account, you can obtain one here - https://confluence.ihtsdotools.org/display/ILS/Confluence+User+Accounts
| Topic | Status | Author | Like | View | Replies | Creation date | Last Reply | Contributors | Category |
|---|
9 Comments
Graham Ponting
HPO and SNOMED cross mapping - a draft mapping has been added to the Community Content page for discussion.
see HPO to SNOMED CT Map - Community Content - SNOMED Confluence (ihtsdotools.org)
Inge Soons
Ian Green I got a question from the Dutch Federation Medical Specialists if there is or is going to be a map between SNOMED and OMIM? What are the current thoughts about that?
Ian Green
Hi Inge,
We had initial discussions with them about 2 years ago. At the time, their were no clear Member requirements to undertake any work, in addition OMIM required us to pay a license fee in perpetuity of $55K per year to "use" OMIM. In view of both of these issues, we did not take the discussions any further
kind regards
Ian
Graham Ponting
I appreciate it may not be what they need, but HPO includes links to OMIM and ORPHA, and has some SNOMED links.
see an example at https://hpo.jax.org/browse/term/HP:0001662
Graham Ponting
Inge Soons
Thank you. Indeed in Orphanet I also found linkages to OMIM. Do you know how those links are maintained and validated?
Ian Green
I agree, it will depend on what the requirements are ?
Ian
Graham Ponting
You will need to ask the HPO team but agreed, that is a critical aspect of any mapping.
Graham
Yiwen Zhuang
Exploratory Study: Standards for Cell, Tissue, and Gene Therapy Products (CTGTP)
Hello, everyone!
I’m Zhuang Yiwen from Singapore, and my team and I are conducting an exploratory study on standards for Cell, Tissue, and Gene Therapy Products (CTGTP).
In Singapore, CTGTPs are regulated by the Health Sciences Authority (HSA) under the Health Products Act (HPA) and the Health Products (Cell, Tissue, and Gene Therapy Products) Regulations 2021. These products are risk-stratified into two classes:
Class 1 CTGTP (lower risk)
Class 2 CTGTP (higher risk)
CTGTP which satisfies ALL the following criteria:
Other CTGTP which are not classified as Class 1 CTGTP
Examples of Class 1:
Examples of Class 2:
Despite this framework, there are currently no mandated standards for representing these products in clinical documentation. To address this gap, our study aims to identify the clinically crucial information that should be captured by exploring current documentation practices.
We Would Love to Hear From You!
We’re reaching out to international public and private hospitals as well as clinical trial facilities to learn about your local documentation practices. Your insights will be invaluable to our study.
Questions:
1. Documentation Practices
(e.g., free-text entries, structured data formats like drop-down menus, or a combination).
2. Standards and Coding Systems
3. Tracking and Recall
Additionally, we welcome any workflows, insights, or inputs from your experience. Every contribution helps! Your feedback will assist us in better understanding global practices and guiding the development of a standardized framework for CTGTP documentation.
Thank you for your time and support.
Zhuang Yiwen
Singapore
Graham Ponting
Hi Zhuang,
Replying as an interested individual terminologist, much of what you ask does not apply to SNOMED as the organisation is not involved directly in patient care, but the International Release of the Terminology is widely used in EPR systems. Elements of the terminology might be involved within the configuration of local systems, to support the information collection. For example a list of blood products is given here;
https://browser.ihtsdotools.org/?perspective=full&conceptId1=410652009&edition=MAIN&release=&languages=en
I hope this clarifies the situation a little.
Graham Ponting